Literature DB >> 7776326

Exercise and cystic fibrosis.

A K Webb1, M E Dodd, J Moorcroft.   

Abstract

Entities:  

Mesh:

Year:  1995        PMID: 7776326      PMCID: PMC1295056     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  59 in total

1.  The sensation of breathlessness.

Authors:  E J CAMPBELL; J B HOWELL
Journal:  Br Med Bull       Date:  1963-01       Impact factor: 4.291

2.  Respiratory muscle function in cystic fibrosis.

Authors:  A Mier; A Redington; C Brophy; M Hodson; M Green
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

3.  Respiratory muscle weakness, pattern of breathing, and CO2 retention in chronic obstructive pulmonary disease.

Authors:  D F Rochester
Journal:  Am Rev Respir Dis       Date:  1991-05

4.  Effect of exercise and physiotherapy in aiding sputum expectoration in adults with cystic fibrosis.

Authors:  W Salh; D Bilton; M Dodd; A K Webb
Journal:  Thorax       Date:  1989-12       Impact factor: 9.139

5.  Oxygen supplementation during exercise in cystic fibrosis.

Authors:  P A Nixon; D M Orenstein; S E Curtis; E A Ross
Journal:  Am Rev Respir Dis       Date:  1990-10

6.  Upper-limb and lower-limb exercise training in patients with chronic airflow obstruction.

Authors:  F R Lake; K Henderson; T Briffa; J Openshaw; A W Musk
Journal:  Chest       Date:  1990-05       Impact factor: 9.410

7.  Maximum intensity exercise training in patients with chronic obstructive pulmonary disease.

Authors:  P A Punzal; A L Ries; R M Kaplan; L M Prewitt
Journal:  Chest       Date:  1991-09       Impact factor: 9.410

8.  Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease.

Authors:  R Casaburi; A Patessio; F Ioli; S Zanaboni; C F Donner; K Wasserman
Journal:  Am Rev Respir Dis       Date:  1991-01

9.  Changes in end-expiratory lung volume during exercise in cystic fibrosis relate to severity of lung disease.

Authors:  J A Regnis; J A Alison; K G Henke; P M Donnelly; P T Bye
Journal:  Am Rev Respir Dis       Date:  1991-09

10.  Exercise in leisure time: coronary attack and death rates.

Authors:  J N Morris; D G Clayton; M G Everitt; A M Semmence; E H Burgess
Journal:  Br Heart J       Date:  1990-06
View more
  12 in total

1.  Validity of a modified shuttle test in adult cystic fibrosis.

Authors:  J Bradley; J Howard; E Wallace; S Elborn
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

Review 2.  Physiotherapy in cystic fibrosis.

Authors:  S A Prasad; E L Tannenbaum; C Mikelsons
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

3.  Exercise testing in children with cystic fibrosis.

Authors:  Diane Rogers; S Ammani Prasad; Iolo Doull
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 4.  Posture and cystic fibrosis.

Authors:  R Tattersall; M J Walshaw
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

5.  Oscillating devices for airway clearance in people with cystic fibrosis.

Authors:  Lisa Morrison; Stephanie Milroy
Journal:  Cochrane Database Syst Rev       Date:  2020-04-30

6.  Exercise testing in cystic fibrosis: why (and how)?

Authors:  D S Urquhart
Journal:  J R Soc Med       Date:  2011-07       Impact factor: 5.344

Review 7.  Exercise recommendations for individuals with cystic fibrosis.

Authors:  S R Boas
Journal:  Sports Med       Date:  1997-07       Impact factor: 11.136

8.  Collagen degrading activity associated with Mycobacterium species.

Authors:  F Massó; A Paéz; E Varela; L D de León; E Zenteno; L F Montaño
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

Review 9.  Oscillating devices for airway clearance in people with cystic fibrosis.

Authors:  Lisa Morrison; Stephanie Innes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-04

Review 10.  A practical approach to oxygen therapy in cystic fibrosis.

Authors:  M E Dodd; C S Haworth; A K Webb
Journal:  J R Soc Med       Date:  1998       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.